Liver transplant for hepatocellular carcinoma in the United States: evolving trends over the last three decades

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author Hashim, Dana
  • dc.contributor.author Haber, Philipp K.
  • dc.contributor.author Dinani, Amreen
  • dc.contributor.author Schiano, Thomas D.
  • dc.contributor.author Asgharpour, Amon
  • dc.contributor.author Kushner, Tatyana
  • dc.contributor.author Kakked, Gaurav
  • dc.contributor.author Tabrizian, Parissa
  • dc.contributor.author Schwartz, Myron
  • dc.contributor.author Gurakar, Ahmet
  • dc.contributor.author Dieterich, Douglas
  • dc.contributor.author Boffetta, Paolo
  • dc.contributor.author Friedman, Scott L.
  • dc.contributor.author Llovet, Josep Maria
  • dc.contributor.author Saberi, Behnam
  • dc.date.accessioned 2022-05-06T06:46:14Z
  • dc.date.available 2022-05-06T06:46:14Z
  • dc.date.issued 2020
  • dc.description.abstract Hepatitis C virus infection has been the most common etiology in HCC-related liver transplantation (LT). Since 2014, direct-acting antivirals (DAAs) have dramatically improved HCV cure. We aimed to study the changing pattern of etiologies and impact in outcome in HCC-related LT according to HCV treatment-era through retrospective analysis of the Scientific Registry of Transplant Recipients (SRTR) database (1987-2017). A total of 27 855 HCC-related liver transplants were performed (median age 59 years, 77% male). In the DAA era (2014-2017) there has been a 14.6% decrease in LT for HCV-related HCC; however, HCV remains the most common etiology in 50% of cases. In the same era, there has been a 50% increase in LT for NAFLD-related HCC. Overall survival was significantly worse for HCV-related HCC compared to NAFLD-related HCC during pre-DAA era (2002-2013; P = .031), but these differences disappeared in the DAA era. In addition, HCV patients had a significant improvement in survival when comparing the DAA era with IFN era (P < .001). Independent predictors of survival were significantly different in the pre-DAA era (HCV, AFP, diabetes) than in the DAA era (tumor size). HCV-related HCC continues to be the main indication for LT in the DAA era, but patients' survival has significantly improved and is comparable to that of NAFLD-related HCC.
  • dc.description.sponsorship Marc Puigvehí received a grant from Asociación Española para el Estudio del Hígado (AEEH). Philipp K. Haber received a grant from the German Research Foundation (DFG). Scott L. Friedman has grant support from NIH RO1DK56621 and U.S. Department of Defense (CA150272P3). Josep M. Llovet is supported by the European Commission (EC)/Horizon 2020 Program (HEPCAR, Ref. 667273–2), U.S. Department of Defense (CA150272P3), an Accelerator Award (CRUCK, AECC, AIRC) (HUNTER, Ref. C9380/A26813), National Cancer Institute, Tisch Cancer Institute (P30-CA196521), Samuel Waxman Cancer Research Foundation, Spanish National Health Institute (SAF2016–76390) and the Generalitat de Catalunya/AGAUR (SGR-1358).
  • dc.format.mimetype application/pdf
  • dc.identifier.citation Puigvehí M, Hashim D, Haber PK, Dinani A, Schiano TD, Asgharpour A, et al. Liver transplant for hepatocellular carcinoma in the United States: evolving trends over the last three dècades. Am J Transplant. 2020 Jan; 20(1): 220-30. DOI: 10.1111/ajt.15576
  • dc.identifier.doi http://dx.doi.org/10.1111/ajt.15576
  • dc.identifier.issn 1600-6135
  • dc.identifier.uri http://hdl.handle.net/10230/53011
  • dc.language.iso eng
  • dc.publisher Wiley
  • dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/667273
  • dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/SAF2016–76390
  • dc.rights This is the peer reviewed version of the following article: Puigvehí M, Hashim D, Haber PK, Dinani A, Schiano TD, Asgharpour A, et al. Liver transplant for hepatocellular carcinoma in the United States: evolving trends over the last three dècades. Am J Transplant. 2020 Jan; 20(1): 220-30, which has been published in final form at http://dx.doi.org/10.1111/ajt.15576. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.subject.keyword Clinical research/practice
  • dc.subject.keyword Liver disease
  • dc.subject.keyword Infectious
  • dc.subject.keyword Liver disease: malignant
  • dc.subject.keyword Liver transplantation/hepatology
  • dc.title Liver transplant for hepatocellular carcinoma in the United States: evolving trends over the last three decades
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/acceptedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)